Recordati Industria Chimica e Farmaceutica SpA
MIL:REC

Watchlist Manager
Recordati Industria Chimica e Farmaceutica SpA Logo
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Watchlist
Price: 52.3 EUR -1.32%
Market Cap: 10.9B EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one REC stock under the Base Case scenario is 66.34 EUR. Compared to the current market price of 52.3 EUR, Recordati Industria Chimica e Farmaceutica SpA is Undervalued by 21%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

REC Relative Value
Base Case
66.34 EUR
Undervaluation 21%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.6
P/S
P/S
Price to Sales
4.6
vs History
69
vs Industry
26
Median 3Y
4.7
Median 5Y
4.9
Industry
2.4
Forward
4.2
More Details
25.9
P/E
P/E
Price to Earnings
25.9
vs History
25
vs Industry
18
Median 3Y
25.4
Median 5Y
25.4
Industry
20.3
Forward
18.9
More Details
18.9
P/OCF
P/OCF
Price to OCF
18.9
vs History
57
vs Industry
21
Median 3Y
18.6
Median 5Y
20
Industry
15.6
More Details
34.8
P/FCFE
P/FCFE
Price to FCFE
34.8
vs History
47
vs Industry
7
Median 3Y
34.5
Median 5Y
35.1
Industry
23.1
More Details
5.7
P/B
P/B
Price to Book Value
5.7
vs History
52
vs Industry
12
Median 3Y
5.7
Median 5Y
5.9
Industry
2
More Details
5.6
EV/S
EV/S
Enterprise Value to Sales
5.6
vs History
49
vs Industry
24
Median 3Y
5.3
Median 5Y
5.5
Industry
2.5
Forward
4.9
More Details
8.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
8.1
vs History
47
vs Industry
27
Median 3Y
7.7
Median 5Y
8
Industry
4.8
More Details
15.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
15.7
vs History
52
vs Industry
24
Median 3Y
15.1
Median 5Y
15.6
Industry
12.5
Forward
13
More Details
19.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
19.7
vs History
36
vs Industry
23
Median 3Y
18.8
Median 5Y
19.1
Industry
15.7
Forward
16.7
More Details
22.9
EV/OCF
EV/OCF
Enterprise Value to OCF
22.9
vs History
39
vs Industry
19
Median 3Y
20.9
Median 5Y
22.1
Industry
14.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
19
Median 3Y
24.6
Median 5Y
24.8
Industry
17.6
More Details
2.9
EV/IC
EV/IC
Enterprise Value to IC
2.9
vs History
73
vs Industry
23
Median 3Y
2.9
Median 5Y
3.2
Industry
1.8
More Details

Multiples Across Competitors

REC Competitors Multiples
Recordati Industria Chimica e Farmaceutica SpA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IT
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
11.2B EUR 4.6 25.9 15.7 19.7
US
Eli Lilly and Co
NYSE:LLY
704.4B USD 15 66.3 35.6 38.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
375.6B USD 4.2 17.4 12.7 16.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.8 19.5 12.8 14.6
CH
Roche Holding AG
SIX:ROG
207.4B CHF 3.5 25.4 9.5 11.1
CH
Novartis AG
SIX:NOVN
178.8B CHF 4.1 17 10.1 13.5
UK
AstraZeneca PLC
LSE:AZN
157.6B GBP 3.9 27.3 130.4 196.6
US
Merck & Co Inc
NYSE:MRK
196.8B USD 3.1 11.5 8.2 9.9
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
130.2B USD 2.1 16.4 7.2 10.1
P/E Multiple
Earnings Growth PEG
IT
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Average P/E: 25.2
25.9
19%
1.4
US
Eli Lilly and Co
NYSE:LLY
66.3
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.4
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.5
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.4
32%
0.8
CH
Novartis AG
SIX:NOVN
17
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.3
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.5
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.4
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IT
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Average EV/EBITDA: 395.4
15.7
11%
1.4
US
Eli Lilly and Co
NYSE:LLY
35.6
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.7
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.5
6%
1.6
CH
Novartis AG
SIX:NOVN
10.1
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.4
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6

See Also

Summary
REC intrinsic value, competitors valuation, and company profile.
DCF Valuation
REC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
REC stock valuation using valuation multiples.
Wall Street Estimates
REC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
REC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.